Maintenance therapy with lurbinectedin and atezolizumab has been found to improve survival outcomes in extensive-stage small cell lung cancer. The combination has been approved by the FDA as a first-line maintenance therapy for this condition. The treatment has shown significant improvements in overall survival and progression-free survival compared to atezolizumab alone.